How much does Tyvyt (Sintilimab Injection) Cost& price without insurance in China?

Tyvyt® is the commercial brand name of Sintilimab Injection, a fully human anti-programmed death 1 (anti-PD-1) monoclonal antibody developed by Innovent Biologics and Eli Lilly. It binds to the PD-1 receptor on T cells, blocking its interaction with PD-L1/PD-L2 to restore anti-tumor immune function.

Main Indications
Treatment of relapsed or refractory classic Hodgkin lymphoma (cHL) in adult patients who have received at least two prior systemic therapies.
First-line treatment of locally advanced or metastatic non-squamous non-small cell lung cancer (NSCLC) in combination with pemetrexed and platinum-based chemotherapy.
First-line treatment of locally advanced or metastatic squamous NSCLC in combination with gemcitabine and platinum-based chemotherapy.
Treatment of unresectable locally advanced or metastatic hepatocellular carcinoma (HCC) in combination with bevacizumab biosimilar.
First-line treatment of locally advanced or metastatic esophageal squamous cell carcinoma (ESCC) in combination with chemotherapy.

Common Side Effects
Common mild adverse reactions: Fever, fatigue, hypothyroidism, rash, pruritus, diarrhea, and nausea.
Laboratory abnormalities: Decreased lymphocyte count, decreased neutrophil count, and elevated liver enzymes.
Severe but uncommon risks: Immune-related adverse events (including pneumonitis, colitis, hepatitis, endocrinopathies), severe infections, and infusion reactions.

Approval Status in China
Tyvyt® (Sintilimab Injection, 100mg/10mL) was officially approved for marketing in China in 2018. It is currently a prescription anti-tumor drug included in China’s National Medical Insurance List.

Buy Tyvyt (Sintilimab Injection) online from China and save up to 80% on costs . no insurance needed . compare prices from a certified HongKong pharmacy .with fast shipping. Contact us now on WhatsApp to get the latest prices.